Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Credit Suisse Lux Biotechnology Equity Fund

+ Add to Watchlist

CR4A:GR

444.2700 EUR 7.4500 1.65%

As of 04:54:30 ET on 04/01/2015.

Snapshot for Credit Suisse Lux Biotechnology Equity Fund (CR4A)

Open: 445.6100 High - Low: 445.6100 - 437.9000 Primary Exchange: Berlin
Volume: 0 52-Week Range: 201.6000 - 472.3200 Beta vs NBI: 0.9577

ETF Chart for CR4A

No chart data available.
  • CR4A:GR 441.7450
  • 1D
  • 1M
  • 1Y
451.7200
Interactive CR4A Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for CR4A

Credit Suisse Lux Biotechnology Equity Fund is a SICAV incorporated in Luxembourg. The Fund is actively managed aiming to outperform the return of the NASDAQ Biotechnology TR benchmark. The Fund mainly invests in equity and equity-type securities of issuers engaged in the biotechnology industry.

Inception Date: 2001-11-06 Telephone: -
Managers: IRENE BEATRICE PUETTNER
Web Site: www.credit-suisse.com

Fundamentals for CR4A

NAV -
Assets (M) (on 2015-03-30) 253.9562
Shares out (M) 0.45
Market Cap (M) 197.73
% Premium -
Average 52-Week % Premium -
Fund Leveraged N

Dividends for CR4A

No dividends reported

Performance for CR4A

1-Month +9.91% 1-Year +95.70%
3-Month +30.93% 3-Year +51.81%
Year To Date +30.93% 5-Year +34.40%
Expense Ratio -

Top Fund Holdings for CR4A

Filing Date: 01/30/2015
Name Position Value % of Total
Biogen Inc 46,745 18,191,284 7.691%
Celgene Corp 150,276 17,906,888 7.571%
Gilead Sciences Inc 162,484 17,033,198 7.202%
Amgen Inc 105,973 16,135,449 6.822%
Incyte Corp 145,000 11,557,950 4.887%
Regeneron Pharmaceuticals Inc 27,000 11,249,820 4.757%
BioMarin Pharmaceutical Inc 115,444 11,216,539 4.742%
Vertex Pharmaceuticals Inc 90,000 9,912,600 4.191%
Alexion Pharmaceuticals Inc 52,752 9,666,276 4.087%
Medivation Inc 80,000 8,705,600 3.681%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil